Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
US Stock Insider Trading | Longeveron disclosed one insider transaction on March 13
On March 13, 2026, Longeveron (LGVN) disclosed a company insider trading activity. Executive Willard Stephen H sold 105.5k shares on March 2, 2026.
【Recent Insider Trades】
【Company Profile】
Longeveron Inc was incorporated as a Delaware limited liability company on October 9, 2014, and authorized to operate in Florida on December 15, 2014. The company is a clinical-stage biotechnology firm developing regenerative medicines to address unmet medical needs. Its primary investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy derived from the bone marrow of young, healthy adult donors. Lomecel-B exhibits multiple mechanisms of action, including pro-vascular, regenerative, and anti-inflammatory effects, promoting tissue repair and healing, with broad potential applications across various disease areas. The company is currently developing three clinical indications: hypoplastic left heart syndrome (HLHS), age-related frailty, and Alzheimer’s disease (AD).